Here are six important trends:
1. The market is expected to grow at a compound annual growth rate of 3.8 percent from 2015 to 2020.
2. The market was valued at $1.6 billion in 2015.
3. Factors such as rapid rise in aging population; rising prevalence of cardiovascular and respiratory system-related diseases; and rising number of emergency surgeries are driving the growth of the market.
4. However, side effects associated with ketamine usage, regulatory issues and lower compliance rates in comparison with other anesthetic drugs are likely to impede the market’s growth.
5. The intravenous segment of the market is expected to account for the largest share in 2015.
6. Major players in the market include AstraZeneca, Baxter International, Hospira and Par Pharmaceutical Companies.
More articles on anesthesia:
Mednax shares increase by 2.71% in the last week: 5 things to know
California Society of Anesthesiologists names Dr. James Moore president: 4 things to note
NAPA names 1st recipients of new honor: 4 quick notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.